<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19438" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Chloroquine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goel</surname>
            <given-names>Pranshul</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pranshul Goel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19438.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Chloroquine is a medication used in the management and treatment of malaria and inflammatory diseases. It is in the sulfonamides class of drugs. This activity describes the indications, action, and contraindications for chloroquine as a valuable agent in the therapy of malaria, rheumatoid arthritis, and lupus erythematosus. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the treatment, prevention, and management of patients with malaria and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the mechanism of action of chloroquine.</p></list-item><list-item><p>Identify the most common adverse effects of chloroquine.</p></list-item><list-item><p>Review the appropriate monitoring of patients treated with chloroquine.</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team that can enhance patient care when prescribing and monitoring chloroquine to improve patient outcomes for patients receiving prophylaxis and treatment with chloroquine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19438&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19438">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19438.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Chloroquine is FDA-approved for the treatment and prophylaxis of uncomplicated malaria in countries where chloroquine-sensitive malaria (certain strains of <italic toggle="yes">P. falciparum</italic>, <italic toggle="yes">P. ovale</italic>, <italic toggle="yes">P. vivax</italic>, and <italic toggle="yes">P. malariae</italic>) is present. These countries include Mexico, areas of Central America to the west of the Panama Canal, the Caribbean, East Asia, as well as some Middle Eastern countries.<xref ref-type="bibr" rid="article-19438.r1">[1]</xref>&#x000a0;The FDA also recommends chloroquine for the treatment of extraintestinal amebiasis.<xref ref-type="bibr" rid="article-19438.r2">[2]</xref> Non-FDA-approved indications of chloroquine include the treatment of certain autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.<xref ref-type="bibr" rid="article-19438.r3">[3]</xref> Also, current research suggests that chloroquine may be helpful as an antitumor medication for the treatment of cancer in association with chemotherapy and radiation.<xref ref-type="bibr" rid="article-19438.r4">[4]</xref></p>
      </sec>
      <sec id="article-19438.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Chloroquine exerts its antimalarial effects by preventing the polymerization of heme into hemozoin (a food source for the malarial parasite). Chloroquine forms a drug-hemozoin complex, and this complex caps the polymerizing chain, thereby preventing additional polymerization. Along with the prevention of polymerization, the free heme accumulates in the food vacuole, exerting its toxic effects on the parasite.<xref ref-type="bibr" rid="article-19438.r5">[5]</xref>&#x000a0;</p>
        <p>Chloroquine also functions as an anti-autoimmune therapy. It exerts its effects by binding to transcriptional factors on T helper 17 cells and preventing differentiation. At the same time, chloroquine also activates the transcription factor Foxp3, driving the formation of regulatory T cells. Regulatory T cells have been shown to treat and prevent autoimmune diseases.<xref ref-type="bibr" rid="article-19438.r3">[3]</xref>&#x000a0;Specifically, for the treatment of rheumatoid arthritis, chloroquine prevents the presentation of autoantigens from MHC class II, therefore, preventing activation of CD4+ T cells.<xref ref-type="bibr" rid="article-19438.r6">[6]</xref></p>
      </sec>
      <sec id="article-19438.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Chloroquine is currently administered orally when used as a prophylaxis for malaria and the treatment of chronic autoimmune diseases.<xref ref-type="bibr" rid="article-19438.r7">[7]</xref>&#x000a0; For malaria prophylaxis, 500 mg is typically administered orally two weeks before, during, and up to 8 weeks after exposure to an endemic area, taken as a weekly dose. When used as a treatment for extraintestinal amoebas, chloroquine dosing 21 mg/kg for three weeks.<xref ref-type="bibr" rid="article-19438.r8">[8]</xref>&#x000a0;Under severe or emergent cases of malaria, chloroquine can be administered parenterally.<xref ref-type="bibr" rid="article-19438.r9">[9]</xref>&#x000a0;Some research has shown that parenteral administration is potentially toxic; therefore, subcutaneous administration has been shown to be a more effective method in circumstances of severe malaria.<xref ref-type="bibr" rid="article-19438.r10">[10]</xref>&#x000a0;For extraintestinal amebiasis, 1g is administered once daily for 2 days, and then 500mg is administered once daily for 14 to 21 days.</p>
      </sec>
      <sec id="article-19438.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Although chloroquine has relatively few side effects when taken as prescribed, higher doses of chloroquine have been shown to have severe adverse effects. The most severe adverse effects associated with high doses of chloroquine include retinal toxicity, long and subtle symptoms of reduced visual acuity, diplopia, and bilateral loss of vision.<xref ref-type="bibr" rid="article-19438.r11">[11]</xref>&#x000a0;High doses have also been shown to cause severe psychiatric issues, such as paranoia, hallucinations, and suicidal ideations.<xref ref-type="bibr" rid="article-19438.r12">[12]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Dermatological reactions include pruritus and photosensitivity.</p>
          </list-item>
          <list-item>
            <p>Retinopathy will typically present with the inability to focus between near and far objects.</p>
          </list-item>
          <list-item>
            <p>Neuropathy can include seizures, paranoia, and hallucinations.</p>
          </list-item>
        </list>
        <p>When administered intramuscularly,&#x000a0;chloroquine has been shown to cause potentially lethal hypotension.<xref ref-type="bibr" rid="article-19438.r13">[13]</xref>&#x000a0;Patients with&#x000a0;glucose-6 phosphate dehydrogenase (G-6-PD) deficiency may cause hemolysis resulting in hemolytic anemia.</p>
      </sec>
      <sec id="article-19438.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Chloroquine has been proven safe to use during pregnancy and in children. Chloroquine has few but serious contraindications. There are reports of cases with death relating to chloroquine administered to patients with porphyria cutaneous tarda.<xref ref-type="bibr" rid="article-19438.r14">[14]</xref>&#x000a0;Chloroquine should not be used in patients with retinal or vision changes unless treating acute malaria. Chloroquine is also contraindicated in patients who suffer from a known hydroxychloroquine sensitivity.</p>
      </sec>
      <sec id="article-19438.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Ideally, chloroquine should be dosed depending on body weight and height. For use as malarial prophylaxis, the appropriate chloroquine dose is 5 mg/kg of body weight with a maximum of around 500 mg given on a once per week dosing regimen.<xref ref-type="bibr" rid="article-19438.r15">[15]</xref>&#x000a0;In patients with&#x000a0;(G-6-PD) deficiency, blood monitoring is recommended to detect any possible hemolytic anemia.</p>
      </sec>
      <sec id="article-19438.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Chloroquine toxicity is rare but has been known to occur when unusually high doses of chloroquine are ingested&#x000a0;or after chronic IV administration. Accidental ingestion has also occurred in children.<xref ref-type="bibr" rid="article-19438.r16">[16]</xref>&#x000a0;When toxicity is present, the most common symptom is retinal toxicity. Treatment of chloroquine toxicity includes mechanical ventilation and administration of diazepam and epinephrine, although these methods have not been a proven method of treatment in all cases.<xref ref-type="bibr" rid="article-19438.r17">[17]</xref></p>
      </sec>
      <sec id="article-19438.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Safely and effectively treating and preventing malaria requires an interprofessional team of healthcare providers, including a clinician, infectious disease specialist, nurse, physician assistant, and pharmacist. Similarly, the treatment of autoimmune and inflammatory conditions requires an interprofessional team consisting of primary care providers, healthcare specialists, and pharmacists. Without proper consultation, patients are at risk of exposure to a very preventable disease. Therefore, the recommended order of steps that the team should take for the prevention and prophylaxis of malaria are as follows:</p>
        <list list-type="order">
          <list-item>
            <p>The patient informs their primary care provider about plans to travel to a country with malaria prevalence. Similarly, a primary care provider may also ask the patient during a normal history and physical whether the patient intends to travel outside of the country they reside.</p>
          </list-item>
          <list-item>
            <p>Once informed of out-of-country travel, the primary care provider will refer the patient to an infectious disease specialist.</p>
          </list-item>
          <list-item>
            <p>The infectious disease specialist can assess the risks of transmission and infection of the patient, depending on the country to which they will be traveling.</p>
          </list-item>
          <list-item>
            <p>Following the risk assessment, the infectious disease specialist can recommend chloroquine as prophylaxis to malaria if the patient will be in a country where chloroquine-sensitive malaria is present.</p>
          </list-item>
          <list-item>
            <p>The pharmacist will provide weight-dependent dosing of chloroquine and provide instructions that maximize the effectiveness of the prophylaxis, such as taking the medication before, during, and after the expected travel.</p>
          </list-item>
          <list-item>
            <p>Nursing staff can also counsel the patient regarding proper dosing and administration and answer any questions that the patient may have regarding the use and adverse events associated with chloroquine.</p>
          </list-item>
        </list>
        <p>The treatment and prevention of malaria do not stop here. First, the patient must abide by the recommended regimen. If the patient fails to follow the regimen, they put themselves at a higher risk of infection.</p>
        <p>Similarly, prescribing chloroquine in the context of inflammatory diseases have a similar recommended course of action:</p>
        <list list-type="order">
          <list-item>
            <p>The patient will come to the primary care provider complaining of symptoms related to autoimmune and/or inflammatory disorders.</p>
          </list-item>
          <list-item>
            <p>The clinician will perform a history and physical and provide proper referrals for the patient's treatment.</p>
          </list-item>
          <list-item>
            <p>Referrals may be necessary for specialists, such as orthopedics and/or genetic counselors.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The specialists can provide the right course of treatment or management of the inflammatory condition, most likely a chronic regimen of medications, including chloroquine.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The pharmacist will adjust the dose depending on the weight and condition of the patient.</p>
          </list-item>
          <list-item>
            <p>As above, nursing staff can offer patient counseling and directions on dosing and administration and adverse events&#x000a0;for which the patient may need to be aware.</p>
          </list-item>
        </list>
        <p>The above exemplified the interprofessional healthcare team approach that makes chloroquine therapy more effective and with fewer adverse events, enhancing patient care. [Level 5]</p>
      </sec>
      <sec id="article-19438.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19438&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19438">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19438/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19438">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19438.s11">
        <title>References</title>
        <ref id="article-19438.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freedman</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice. Malaria prevention in short-term travelers.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Aug</month>
            <day>07</day>
            <volume>359</volume>
            <issue>6</issue>
            <fpage>603</fpage>
            <page-range>603-12</page-range>
            <pub-id pub-id-type="pmid">18687641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <chapter-title>Sulfonamides</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>12</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">31643703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toh</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Leblanc</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Chloroquine modulates inflammatory autoimmune responses through Nurr1 in autoimmune diseases.</article-title>
            <source>Sci Rep</source>
            <year>2019</year>
            <month>Oct</month>
            <day>29</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>15559</fpage>
            <pub-id pub-id-type="pmid">31664129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plantone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koudriavtseva</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.</article-title>
            <source>Clin Drug Investig</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>653</fpage>
            <page-range>653-671</page-range>
            <pub-id pub-id-type="pmid">29737455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sullivan</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gluzman</surname>
                <given-names>IY</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>On the molecular mechanism of chloroquine's antimalarial action.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1996</year>
            <month>Oct</month>
            <day>15</day>
            <volume>93</volume>
            <issue>21</issue>
            <fpage>11865</fpage>
            <page-range>11865-70</page-range>
            <pub-id pub-id-type="pmid">8876229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of hydroxychloroquine as an antirheumatic drug.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>2 Suppl 1</issue>
            <fpage>82</fpage>
            <page-range>82-91</page-range>
            <pub-id pub-id-type="pmid">8278823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Pfeil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Continuous oral chloroquine as a novel route for Plasmodium prophylaxis and cure in experimental murine models.</article-title>
            <source>BMC Res Notes</source>
            <year>2011</year>
            <month>Jul</month>
            <day>28</day>
            <volume>4</volume>
            <fpage>262</fpage>
            <pub-id pub-id-type="pmid">21798062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ursing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eksborg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rombo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bergqvist</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Blessborn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kofoed</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Chloroquine is grossly under dosed in young children with malaria: implications for drug resistance.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>e86801</fpage>
            <pub-id pub-id-type="pmid">24466245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Watt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bergqvist</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Njelesani</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>Parenteral chloroquine for treating falciparum malaria.</article-title>
            <source>J Infect Dis</source>
            <year>1987</year>
            <month>Feb</month>
            <volume>155</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-201</page-range>
            <pub-id pub-id-type="pmid">3543146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Churchill</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Greenwood</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations.</article-title>
            <source>N Engl J Med</source>
            <year>1988</year>
            <month>Dec</month>
            <day>08</day>
            <volume>319</volume>
            <issue>23</issue>
            <fpage>1493</fpage>
            <page-range>1493-500</page-range>
            <pub-id pub-id-type="pmid">3054558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braga</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Cayotopa</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Schlosser</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>de Souza</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Filgueira-J&#x000fa;nior</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>Wde J</given-names>
              </name>
              <name>
                <surname>da Silva-Nunes</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Side Effects of Chloroquine and Primaquine and Symptom Reduction in Malaria Endemic Area (M&#x000e2;ncio Lima, Acre, Brazil).</article-title>
            <source>Interdiscip Perspect Infect Dis</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>346853</fpage>
            <pub-id pub-id-type="pmid">26357512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lysack</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Lysack</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kvern</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>A severe adverse reaction to mefloquine and chloroquine prophylaxis.</article-title>
            <source>Aust Fam Physician</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>12</issue>
            <fpage>1119</fpage>
            <page-range>1119-20</page-range>
            <pub-id pub-id-type="pmid">9919736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prakongpan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sirimai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>An improved formulation of chloroquine for intramuscular administration: absorption kinetics in rabbits.</article-title>
            <source>J Pharm Pharmacol</source>
            <year>1989</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>10</issue>
            <fpage>726</fpage>
            <page-range>726-8</page-range>
            <pub-id pub-id-type="pmid">2575156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drasch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eisenmenger</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>[Death following administration of 1,250 mg chloroquine in porphyria cutanea tarda].</article-title>
            <source>Z Rechtsmed</source>
            <year>1986</year>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>285</fpage>
            <page-range>285-93</page-range>
            <pub-id pub-id-type="pmid">3577436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dresser</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Chloroquine dose for malaria prevention.</article-title>
            <source>Can Fam Physician</source>
            <year>1986</year>
            <month>Feb</month>
            <volume>32</volume>
            <fpage>231</fpage>
            <pub-id pub-id-type="pmid">21267237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wittes</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions to chloroquine and amodiaquine as used for malaria prophylaxis: a review of the literature.</article-title>
            <source>Can Fam Physician</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>33</volume>
            <fpage>2644</fpage>
            <page-range>2644-9</page-range>
            <pub-id pub-id-type="pmid">21264010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19438.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clemessy</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Taboulet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hantson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barriot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bismuth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baud</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of acute chloroquine poisoning: a 5-year experience.</article-title>
            <source>Crit Care Med</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>1189</fpage>
            <page-range>1189-95</page-range>
            <pub-id pub-id-type="pmid">8674334</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
